131 related articles for article (PubMed ID: 22648001)
21. Intact fibroblast growth factor-23 in plasma from Gambian children: response to the letter from Smith et al.
Braithwaite V; Bruggraber SF; Prentice A
Osteoporos Int; 2013 Jun; 24(6):1935-6. PubMed ID: 23288027
[No Abstract] [Full Text] [Related]
22. Aetiology of nutritional rickets in rural Bangladeshi children.
Ahmed S; Goldberg GR; Raqib R; Roy SK; Haque S; Braithwaite VS; Pettifor JM; Prentice A
Bone; 2020 Jul; 136():115357. PubMed ID: 32276153
[TBL] [Abstract][Full Text] [Related]
23. C-terminal FGF23 fragments: present but not seen?
Smith ER; McMahon LP; Holt SG
Osteoporos Int; 2013 Jun; 24(6):1933-4. PubMed ID: 23288025
[No Abstract] [Full Text] [Related]
24. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
25. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
[TBL] [Abstract][Full Text] [Related]
26. Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.
Hanudel MR; Wesseling-Perry K; Gales B; Ramos G; Campbell V; Ethridge K; Scotti M; Elashoff DA; Alejos J; Reemtsen B; Salusky IB
Pediatr Nephrol; 2016 Apr; 31(4):661-9. PubMed ID: 26525200
[TBL] [Abstract][Full Text] [Related]
27. Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children.
Kunert SK; Hartmann H; Haffner D; Leifheit-Nestler M
J Bone Miner Metab; 2017 Mar; 35(2):215-226. PubMed ID: 27017221
[TBL] [Abstract][Full Text] [Related]
28. Serum fibroblast growth factor 23 is a useful marker to distinguish vitamin D-deficient rickets from hypophosphatemic rickets.
Kubota T; Kitaoka T; Miura K; Fujiwara M; Ohata Y; Miyoshi Y; Yamamoto K; Takeyari S; Yamamoto T; Namba N; Ozono K
Horm Res Paediatr; 2014; 81(4):251-7. PubMed ID: 24577200
[TBL] [Abstract][Full Text] [Related]
29. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
30. Technical and diagnostic performance of a new fully automated immunoassay for the determination of intact fibroblast growth factor 23 (FGF23).
van Helden J; Weiskirchen R
Scand J Clin Lab Invest; 2018; 78(7-8):584-590. PubMed ID: 30380963
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
32. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
Frishberg Y; Ito N; Rinat C; Yamazaki Y; Feinstein S; Urakawa I; Navon-Elkan P; Becker-Cohen R; Yamashita T; Araya K; Igarashi T; Fujita T; Fukumoto S
J Bone Miner Res; 2007 Feb; 22(2):235-42. PubMed ID: 17129170
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
34. Determination of fibroblast growth factor 23.
Heijboer AC; Levitus M; Vervloet MG; Lips P; ter Wee PM; Dijstelbloem HM; Blankenstein MA
Ann Clin Biochem; 2009 Jul; 46(Pt 4):338-40. PubMed ID: 19564163
[TBL] [Abstract][Full Text] [Related]
35. Association between plasma fibroblast growth factor 23 and left ventricular mass index in patients with Takayasu arteritis.
Cheng N; He Y; Dang A; Lv N; Wang X; Li H
Clin Rheumatol; 2020 May; 39(5):1591-1599. PubMed ID: 31897962
[TBL] [Abstract][Full Text] [Related]
36. Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study.
di Giuseppe R; Kühn T; Hirche F; Buijsse B; Dierkes J; Fritsche A; Kaaks R; Boeing H; Stangl GI; Weikert C
PLoS One; 2015; 10(7):e0133580. PubMed ID: 26193703
[TBL] [Abstract][Full Text] [Related]
37. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
[TBL] [Abstract][Full Text] [Related]
38. Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation.
Bansal S; Friedrichs WE; Velagapudi C; Feliers D; Khazim K; Horn D; Cornell JE; Werner SL; Fanti P
Nephrol Dial Transplant; 2017 Jun; 32(6):960-968. PubMed ID: 27836924
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis of patients with FGF23-related hypophosphatemic rickets.
Kinoshita Y; Saito T; Shimizu Y; Hori M; Taguchi M; Igarashi T; Fukumoto S; Fujita T
Eur J Endocrinol; 2012 Aug; 167(2):165-72. PubMed ID: 22577109
[TBL] [Abstract][Full Text] [Related]
40. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
